GlassScriptPhysician profile
Sydney Miggantz
NPI 1457099061
$2,138.18
in general payments reported to CMS, 2019-2025
12 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $127 · 2023: $696 · 2024: $390 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $559.51 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Bioventus LLC | $310.60 | 2022-2023 | Exogen Ultrasound Bone Healing System |
| Stryker Corporation | $211.60 | 2025 | Citrefix, 7 X 23mm Citrelock Implant, Allomatrix |
| Aroa Biosurgery Incorporated | $183.30 | 2024 | |
| Kerecis Limited | $143.04 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Depuy Synthes Sales INC. | $140.61 | 2025 | Na |
| Organogenesis INC. | $138.74 | 2025 | Puraply Wound Matrix |
| Horizon Therapeutics Plc | $123.50 | 2023 | Krystexxa |
| Smith+Nephew, INC. | $120.06 | 2025 | Grafix Pl, Allevyn Heel 10.5cm X 13.5cm Ctn 5, Collagenase Santyl |
| Nevro Corp. | $117.61 | 2023 | Senza |
| Reapplix INC. | $71.13 | 2025 | 3c Patch Kit - Box |
| Paratek Pharmaceuticals, INC. | $18.48 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Miggantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.